Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris-A Case Report.

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder that can severely impact the quality of life in patients, particularly when presenting in chronic or refractory form. Emerging evidence suggests that JAK inhibitors may offer a potential treatment option. Here, we present a case of refractory PRP successfully treated with tofacitinib.